drugset / Trial / NCT01901185

Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept

NCT01901185

Phase 3 Completed 77 enrolled Amgen
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the ability of people with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) to use an experimental autoinjector to self inject etanercept (Enbrel®).

Timeline

Start
2013-06-11
Primary completion
2013-12-18
Completion
2013-12-30

Drugs

EvaluationDrugModalityDoseRoute
Background Etanercept Protein / enzyme biologic 50 mg Subcutaneous

Indications